Tiwari Sanjay, Dong Hongli, Kim Eun Jung, Weintraub Lewis, Epstein Paul M, Lerner Adam
Evans Department of Medicine, Section of Hematology and Oncology, Boston Medical Center, 650 Albany Street, Boston, MA 02118, USA.
Biochem Pharmacol. 2005 Feb 1;69(3):473-83. doi: 10.1016/j.bcp.2004.10.009. Epub 2004 Dec 15.
cAMP-mediated signaling potentiates glucocorticoid-mediated apoptosis in lymphoid cells, but an effective means by which to take advantage of this observation in the treatment of lymphoid malignancies has not been identified. The primary objective of the current study was to determine whether PDE4 inhibitors, a class of compounds in late clinical development that raise intracellular cAMP levels by inhibiting type 4 cyclic nucleotide phosphodiesterases (PDE4), increase the efficacy of glucocorticoid-mediated apoptosis in leukemic cells from patients with B cell chronic lymphocytic leukemia (B-CLL). Rolipram, a prototypic PDE4 inhibitor, synergized with glucocorticoids in inducing B-CLL but not T cell apoptosis. Rolipram also augmented glucocorticoid receptor element (GRE) transactivation in B-CLL cells. In contrast, inhibition of protein kinase A (PKA) with the cAMP antagonist Rp-8Br-cAMPS reversed both glucocorticoid-induced apoptosis and GRE transactivation. CCRF-CEM cells, a well-studied model of glucocorticoid and cAMP-induced apoptosis, differed from B-CLL cells in that stimulation of adenylyl cyclase with the diterpene forskolin was required to increase both glucocorticoid-mediated apoptosis and GRE activation, while PDE4 inhibition had no effect. Consistent with these results, inhibition of PDE4 induced cAMP elevation in B-CLL but not CCRF-CEM cells, while forskolin augmented cAMP levels in CCRF-CEM but not B-CLL cells. While rolipram treatment up-regulated PDE4B in B-CLL, forskolin treatment up-regulated PDE4D in CCRF-CEM cells. These studies suggest that PKA is required for and enhances glucocorticoid-induced apoptosis in B-CLL by modulating glucocorticoid receptor signal transduction. Clinical trials that examine whether PDE4 inhibitors enhance the efficacy of glucocorticoid-containing chemotherapy regimens in B-CLL are indicated.
环磷酸腺苷(cAMP)介导的信号传导增强了淋巴细胞中糖皮质激素介导的细胞凋亡,但尚未确定在治疗淋巴系统恶性肿瘤中利用这一观察结果的有效方法。本研究的主要目的是确定磷酸二酯酶4(PDE4)抑制剂(一类处于临床后期开发阶段的化合物,通过抑制4型环核苷酸磷酸二酯酶(PDE4)提高细胞内cAMP水平)是否能增加糖皮质激素介导的B细胞慢性淋巴细胞白血病(B-CLL)患者白血病细胞凋亡的疗效。罗利普兰是一种典型的PDE4抑制剂,它与糖皮质激素协同诱导B-CLL细胞凋亡,但不诱导T细胞凋亡。罗利普兰还增强了B-CLL细胞中糖皮质激素受体元件(GRE)的反式激活。相反,用cAMP拮抗剂Rp-8Br-cAMPS抑制蛋白激酶A(PKA)可逆转糖皮质激素诱导的细胞凋亡和GRE反式激活。CCRF-CEM细胞是一种经过充分研究的糖皮质激素和cAMP诱导细胞凋亡的模型,与B-CLL细胞不同,需要用二萜类化合物福斯高林刺激腺苷酸环化酶来增加糖皮质激素介导的细胞凋亡和GRE激活,而抑制PDE4则没有效果。与这些结果一致,抑制PDE4可诱导B-CLL细胞而非CCRF-CEM细胞内cAMP升高,而福斯高林可增加CCRF-CEM细胞而非B-CLL细胞内的cAMP水平。虽然罗利普兰治疗可上调B-CLL细胞中的PDE4B,但福斯高林治疗可上调CCRF-CEM细胞中的PDE4D。这些研究表明,PKA通过调节糖皮质激素受体信号转导,对B-CLL中糖皮质激素诱导的细胞凋亡是必需的且可增强其作用。因此有必要进行临床试验,以研究PDE4抑制剂是否能提高含糖皮质激素的化疗方案对B-CLL的疗效。